Heart failure and inhibition of renin–angiotensin–aldosterone system

Publication date: June 2018Source: Cor et Vasa, Volume 60, Issue 3Author(s): Jiří Vítovec, Jindřich Špinar, Lenka ŠpinarováAbstractA historical survey is presented of mortality clinical trials focussed on the inhibition of the renin–angiotensin–aldosterone system on different levels in patients with chronic heart failure. The first study, CONSENSUS, was published in 1987 and showed that the ACE-inhibitor enalapril clearly reduced mortality in severe heart failure compared with placebo. This was followed by studies with beta blockers, angiotensin II type 1 receptor blockers, blockers of mineralocorticoid receptors, and direct renin inhibitors.A recent study, PARADIGM, comparing dual inhibitor of neprilysin and antiotensin II receptor (LCZ696) with enalapril, was terminated prematurely for a significant effect of inhibiting neprilysin and valsartan.
Source: Cor et Vasa - Category: Cardiology Source Type: research